First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advancedEGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study-Reference-Cited by-同舟云学术

First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advancedEGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study

Published:2017-10 Issue:10 Volume:28 Page:2443-2450
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Shi Y.K.,Wang L.,Han B.H.,Li W.,Yu P.,Liu Y.P.,Ding C.M.,Song X.,Ma Z.Y.,Ren X.L.,Feng J.F.,Zhang H.L.,Chen G.Y.,Han X.H.,Wu N.,Yao C.,Song Y.,Zhang S.C.,Song W.,Liu X.Q.,Zhao S.J.,Lin Y.C.,Ye X.Q.,Li K.,Shu Y.Q.,Ding L.M.,Tan F.L.,Sun Y.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/28/10/2443/20232736/mdx359.pdf

Reference20 articles.

1. Cancer statistics, 2016;Siegel;CA Cancer J Clin,2016

2. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer;Scagliotti;J Clin Oncol,2008

3. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study;Bover;Lancet,2009

4. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial

5. Epidermal growth factor receptor mutations in lung cancer;Sharma;Nat Rev Cancer,2007

Cited by 240 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. EGFR-TKIs or EGFR-TKIs combination treatments for untreated advanced EGFR- mutated NSCLC: a network meta-analysis;2024-09-11

2. Novel Combination of Therapeutic Approaches in Advanced NSCLC with EGFR Activating Mutations;Targets;2024-09-07

3. Appropriate delay of primary tumour radiotherapy may lead to better long-term overall survival for non-small cell lung cancer treated with EGFR-TKIs;BMC Cancer;2024-08-26

4. Strong PD-L1 affect clinical outcomes in advanced NSCLC treated with third-generation EGFR-TKIs;Future Oncology;2024-08-19

5. Volatile organic compounds in exhaled breath: a promising approach for accurate differentiation of lung adenocarcinoma and squamous cell carcinoma;Journal of Breath Research;2024-08-05